CranioSense

CranioSense is a clinical-stage medical technology company based in Boston, specializing in non-invasive measurement and management of intracranial pressure (ICP) for patients with traumatic brain injuries (TBI). The company has developed the IPASS (Intracranial Pressure and Assessment Screening System), which allows for rapid ICP measurement without invasive procedures. The system includes a forehead patch, clip-on sensors, and a handheld device, enabling quick triage and continuous monitoring of ICP. CranioSense's technology has been validated through multiple studies, demonstrating high sensitivity and specificity in detecting intracranial hypertension. The company targets hospitals, intensive care units, neurointensivists, paramedics, and other healthcare providers, particularly in pre-hospital and rural settings where traditional ICP monitoring may not be feasible. Recognized for its innovation, CranioSense won the 2023 National Cade Prize for Innovation and continues to advance its technology through clinical validation and partnerships with leading medical institutions.

• Employees 5
• Founded 2022